TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA expanded remibrutinib’s indication to include adults with symptomatic dermographism whose symptoms are inadequately controlled by H1 antihistamines. In the phase III RemIND trial cohort, complete responses at 12 weeks occurred in 29.3% of participants taking remibrutinib and 14.0% taking placebo.
The FDA has expanded remibrutinib’s approved use to treat adults with symptomatic dermographism whose condition is inadequately controlled by H1 antihistamines, Novartis announced. The decision adds a chronic inducible urticaria condition to the drug’s uses and is supported by phase III trial results showing higher rates of complete response than placebo.
Remibrutinib, sold under the brand name Rhapsido, is an oral Bruton’s tyrosine kinase (BTK) inhibitor. The newly expanded indication covers adults with symptomatic dermographism who remain inadequately controlled by H1 antihistamines. The source report describes the medicine as an initial treatment option for this group; it does not provide further prescribing instructions or dosing details.
The approval’s principal trial support came from the symptomatic dermographism cohort of the phase III RemIND trial. Participants had chronic inducible urticaria that remained symptomatic despite treatment with second-generation H1 antihistamines. Researchers compared remibrutinib with placebo, using the Total Fric Score to assess complete response.
At 12 weeks, 29.3% of participants receiving remibrutinib met the trial’s complete-response criteria, compared with 14.0% receiving placebo (P=0.0229). The report says responses were observed as early as two weeks after treatment began. In clinical trials with follow-up to 24 weeks, the reported safety profile was consistent; adverse events occurring in at least 3% of patients included nasal congestion, sore throat, nasopharyngitis, bleeding, headache, nausea and abdominal pain.
A New Approved Option for Dermographism
The FDA decision gives eligible adults with symptomatic dermographism an approved oral treatment option when H1 antihistamines have not adequately controlled their symptoms. That matters for a condition the source describes as having historically limited treatment options. The trial results show a higher complete-response rate with remibrutinib than with placebo, while also indicating that most participants in the treatment group did not meet the complete-response threshold at 12 weeks.
Novartis said remibrutinib is the first prescription drug approved for both chronic spontaneous urticaria and symptomatic dermographism. The company also said these conditions collectively occur in more than 90% of patients with chronic hives. That is a company-reported framing of the drug’s coverage across two conditions; the approval itself applies to the specified adult dermographism population and does not mean every patient with chronic hives is eligible or will respond.
As an affiliate, we earn on qualifying purchases.
From Chronic Hives to Dermographism
Symptomatic dermographism is described in the report as the most common form of chronic inducible urticaria. Chronic inducible urticaria refers to hives brought on by a trigger, distinguishing it from chronic spontaneous urticaria, in which hives occur without a consistent external trigger. The article does not provide a detailed clinical description of symptoms or diagnostic criteria.
Before this expanded indication, remibrutinib was approved for chronic spontaneous urticaria. The FDA’s latest action extends its approved use to symptomatic dermographism, based principally on the RemIND trial cohort for that condition. The trial enrolled people who remained symptomatic despite second-generation H1 antihistamine treatment, so its results directly address the population named in the new indication.
H1 antihistamine alternative treatments
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Available Trial Details
The source report provides the 12-week response rates and a safety follow-up period of up to 24 weeks, but it does not give the number of participants in the dermographism cohort, detailed trial methods, or results beyond that follow-up period. It also does not describe how the FDA weighed individual safety findings or provide the full prescribing information.
The reported complete-response percentages do not establish how long responses last or how an individual patient will fare. The source lists adverse events reported in at least 3% of patients but does not provide their individual rates, severity, or comparison with placebo. Those details, along with any additional safety warnings and prescribing requirements, are not included in the material supplied.
chronic inducible urticaria medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Prescribing Details and Longer Follow-Up
Remibrutinib is now approved for the stated adult symptomatic dermographism population, according to the announcement. Clinicians and patients will need to consult the FDA-approved prescribing information for full directions, warnings and details not covered in the report. The source does not specify when the updated label will be available or describe a further regulatory milestone.
Further information about longer-term outcomes, response durability and adverse-event rates would help clarify how the trial findings apply in routine care. The report does not announce additional RemIND results or a planned follow-up publication, so the timing and availability of those details remain unknown.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA approve?
The FDA expanded remibrutinib’s indication to include adults with symptomatic dermographism whose condition is inadequately controlled by H1 antihistamines.
What were the phase III trial results?
In the symptomatic dermographism cohort of the RemIND trial, 29.3% of participants taking remibrutinib achieved a complete response at 12 weeks, compared with 14.0% taking placebo (P=0.0229), according to the report.
How soon were responses observed?
The report says responses were observed as early as two weeks after participants started remibrutinib. It does not say that every patient responded by that point.
What adverse events were reported?
In clinical trials with follow-up to 24 weeks, adverse events occurring in at least 3% of patients included nasal congestion, sore throat, nasopharyngitis, bleeding, headache, nausea and abdominal pain. Consult a qualified healthcare professional for individual medical decisions and the full prescribing information.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
